CN112955166A - 治疗咬肌肥大的方法 - Google Patents

治疗咬肌肥大的方法 Download PDF

Info

Publication number
CN112955166A
CN112955166A CN201980069678.6A CN201980069678A CN112955166A CN 112955166 A CN112955166 A CN 112955166A CN 201980069678 A CN201980069678 A CN 201980069678A CN 112955166 A CN112955166 A CN 112955166A
Authority
CN
China
Prior art keywords
units
botulinum toxin
muscle
masseter
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980069678.6A
Other languages
English (en)
Chinese (zh)
Inventor
E·李
B·鲍文
C·索莫吉
J·D·罗格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN112955166A publication Critical patent/CN112955166A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Traffic Control Systems (AREA)
CN201980069678.6A 2018-09-13 2019-09-12 治疗咬肌肥大的方法 Pending CN112955166A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731064P 2018-09-13 2018-09-13
US62/731,064 2018-09-13
PCT/US2019/050910 WO2020056204A1 (en) 2018-09-13 2019-09-12 Methods for treatment of masseter muscle hypertrophy

Publications (1)

Publication Number Publication Date
CN112955166A true CN112955166A (zh) 2021-06-11

Family

ID=68069888

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980069678.6A Pending CN112955166A (zh) 2018-09-13 2019-09-12 治疗咬肌肥大的方法

Country Status (11)

Country Link
US (3) US20200085923A1 (https=)
EP (1) EP3849585A1 (https=)
JP (2) JP2022500417A (https=)
KR (1) KR20210057106A (https=)
CN (1) CN112955166A (https=)
AU (2) AU2019337656A1 (https=)
BR (1) BR112021004776A2 (https=)
CA (1) CA3112227A1 (https=)
MX (1) MX2021002993A (https=)
TW (2) TW202434280A (https=)
WO (1) WO2020056204A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230152107A (ko) * 2021-02-26 2023-11-02 이온 바이오파마, 인크. 두통을 치료하는 데 사용하기 위한 신경독소 조성물

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115139A1 (en) * 2002-10-15 2004-06-17 Allergan, Inc. Botulinum toxin dental therapies and procedures
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20060147471A1 (en) * 2005-01-03 2006-07-06 Borodic Gary E Compositions, methods and devices for preparing less painful Botulinum toxin formulations
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
CN102078597A (zh) * 2000-10-04 2011-06-01 阿勒根公司 用于治疗肌肉损伤的方法
CN105209014A (zh) * 2013-05-15 2015-12-30 波斯蒂贸易有限公司 含有肉毒杆菌神经毒素的药物组合物及其应用
WO2017075468A1 (en) * 2015-10-29 2017-05-04 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102078597A (zh) * 2000-10-04 2011-06-01 阿勒根公司 用于治疗肌肉损伤的方法
US20040115139A1 (en) * 2002-10-15 2004-06-17 Allergan, Inc. Botulinum toxin dental therapies and procedures
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20060147471A1 (en) * 2005-01-03 2006-07-06 Borodic Gary E Compositions, methods and devices for preparing less painful Botulinum toxin formulations
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
CN105209014A (zh) * 2013-05-15 2015-12-30 波斯蒂贸易有限公司 含有肉毒杆菌神经毒素的药物组合物及其应用
WO2017075468A1 (en) * 2015-10-29 2017-05-04 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BURCU BAŞ等: "Treatment of masseteric hypertrophy with botulinum toxin:A report of two cases", 《MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL》, vol. 15, no. 4, 1 July 2010 (2010-07-01), pages 649 *

Also Published As

Publication number Publication date
WO2020056204A1 (en) 2020-03-19
KR20210057106A (ko) 2021-05-20
EP3849585A1 (en) 2021-07-21
MX2021002993A (es) 2021-08-11
JP2024177185A (ja) 2024-12-19
TW202023606A (zh) 2020-07-01
AU2025226702A1 (en) 2025-09-25
TWI835858B (zh) 2024-03-21
US20200085923A1 (en) 2020-03-19
US20230080740A1 (en) 2023-03-16
BR112021004776A2 (pt) 2021-11-09
JP2022500417A (ja) 2022-01-04
TW202434280A (zh) 2024-09-01
AU2019337656A1 (en) 2021-05-06
CA3112227A1 (en) 2020-03-19
US20230083250A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
US20240050540A1 (en) Neurotoxin compositions for use in treating headache
US20240342256A1 (en) Injection paradigm for administration of botulinum toxins
US5183462A (en) Controlled administration of chemodenervating pharmaceuticals
TWI234462B (en) Methods for treating pain
US10729751B2 (en) Injection paradigm for administration of botulinum toxins
Rzany et al. Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview
JP2020158521A (ja) Ｅｆｐの治療または低減方法
AU2025226702A1 (en) Methods for treatment of masseter muscle hypertrophy
JP2021505570A (ja) 高い応答率及び長い効果の持続期間を有する注射可能なボツリヌス毒素製剤及びその使用方法
US9492513B2 (en) Methods for treatment of hip and groin pain associated with femoroacetabular impingement (FAI)
AU2015315571A1 (en) Methods for treating osteoarthritis pain
US20250018016A1 (en) Botulinum neurotoxin composition
US20250186328A1 (en) Use of botulinum toxins for the treatment of platysma prominence
Grenda et al. The usefulness of botulinum toxin injections in oncology–Clinical and laboratory perspectives
Pickett Advances in non-surgical facial aesthetics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination